20 Nov 2025: The ISH was pleased to be part of the Chinese Hypertension Meeting (CHM) 2025 held in the city of Chengdu from 31 October to 2 November 2025.

This year’s meeting gathered over 2,000 participants across nine halls and nearly one hundred scientific sessions.

Conference Chairman Jiguang Wang delivered the inaugural address, highlighting ongoing challenges in hypertension control and calling for strengthened innovation and academic collaboration. He emphasized the need to significantly improve national hypertension control rates in the coming years and to advance the development of a high-quality prevention and treatment system.

Yan Li, ISH Council member and Chair of the ISH Women in Hypertension Research Committee, and Yuqing Zhang, Chair of the ISH Asia Pacific RAG, were among the Conference Chairs.

Prominent international and domestic experts at the meeting included Rhian Touyz (Past President of the ISH), Niamh Chapman (former Chair of the ISH Women in Hypertension Research Committee, Dean Picone (Chair of the ISH New Investigator Committee), and Yook Chin Chia (ISH Asia Pacific RAG member).

Wang Jiguang’s plenary lecture focused on innovation and progress in hypertension treatment. He offered a structured overview of emerging breakthroughs and trends – from drug development and mechanistic innovation to future prevention goals. He highlighted the move toward more precise mechanisms, longer-acting therapies, advances in interventional treatment for resistant hypertension, and the importance of standardized screening for secondary hypertension. He emphasized the need for technological innovation,integrated prevention-treatment-care, multidisciplinary collaboration, and broad public engagement.

Rhian Touyz presented on latest updates in the American and European hypertension guidelines. She compared the simplified European Society of Cardiology classification (unraised, elevated, hypertension) with the more detailed American College of Cardiology/American Heart Association staging. Both guidelines emphasize cardiovascular risk–stratified management, out-of-office blood pressure monitoring, and earlier intervention in high-risk individuals. She described the trend toward more intensive blood pressure targets (e.g., SBP 120–129 mmHg in treated patients) and clarified the limited but conditional role of interventional therapy for refractory hypertension. She also shared Canada’s successful experiences in improving hypertension control rates.

The conference supported experts at all careers stages, providing travel grants to 181 registered physicians and offered registration discounts or waivers to more than 600 physicians.

With thanks to the Secretariat of the CHM2025 Conference for sharing information and pictures relating to the meeting.